It is intended that such research will demonstrate complementary synergy of cotreatment with metformin and vorinostat on TKI sensitivity, thus providing a new therapeutic approach that could be generally adopted to treat NSCLC patients with EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.